Therapeutics Articles
While a cure for Alzheimer’s remains elusive, new diagnostic tools and treatment options are improving patient quality of life.
Exciting new developments in gene therapy and genome editing show promise for treating a variety of genetic diseases.
RSV infections account for a large share of U.S. hospitalizations for lower respiratory tract disease due in large part to a lack of immunization and prophylactic therapies, but new developments and cutting-edge therapies may soon become standard medical practice.
While acetylcholinesterase inhibitors, corticosteroids and thymectomy are generally considered first-line therapies for MG, many patients additionally require proven immunosuppressive therapies (ISTs) such as azathioprine, cyclosporine/tacrolimus or mycophenolate mofetil, or immunomodulatory therapies, including intravenous immune globulin (IVIG) or plasma exchange (PLEX).
Understanding the factors contributing to the current shortage of immune globulin could help to address a crisis that threatens dire consequences for patients.
Will genetic testing and whole genome sequencing become part of the standard of care in treating patients?
Newly created treatments for high-risk COVID-19 patients have proved highly effective. Unfortunately, challenges with their distribution and administration have limited their use.
While there may be no “magic bullet” to treat cytokine storm, one widely used immunomodulatory agent in particular — polyclonal intravenous immune globulin (IVIG) purified from healthy donor plasma — is distinguished by the simple fact that it is anything but a narrowly targeted treatment.
As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.
Studies shed light on whether high-dose intravenous immune globulin, convalescent plasma and hyperimmune globulin will be effective therapeutic options for the novel coronavirus.
Optimism continues to grow about the use of stem cells in regenerative medicine highlighted by hundreds of successful clinical trials.
Findings suggest CSL112 can boost cholesterol efflux capacity in patients with impaired endogenous HDL function. Encouragingly, several studies have documented its ability to reduce atherosclerotic plaque volume.
